From: Adenosine A2b receptor promotes progression of human oral cancer
Clinical classification | Total | Results of immunostaining | p value | |
---|---|---|---|---|
No. patients (%) | ||||
ADORA2B negative | ADORA2B positive | |||
Age at surgery (years) | ||||
 <60 | 27 | 7 (26) | 20 (74) | 0.95 |
 ≧60, <70 | 26 | 8 (31) | 18 (69) | |
 ≧70 | 47 | 13 (28) | 34 (72) | |
Gender | ||||
 Male | 64 | 21 (33) | 43 (67) | 0.24 |
 Female | 36 | 7 (19) | 29 (81) | |
T-primary tumor | ||||
 T1 | 8 | 3 (38) | 5 (62) | 0.02* |
 T2 | 60 | 22 (37) | 38 (63) | |
 T3 | 15 | 2 (13) | 13 (87) | |
 T4 | 17 | 1 (6) | 16 (94) | |
 T1 + T2 | 58 | 25 (43) | 33 (57) | 0.01* |
 T3 + T4 | 32 | 3 (10) | 29 (90) | |
N-regional lymph node | ||||
 N (negative) | 58 | 14 (24) | 44 (76) | 0.39 |
 N (positive) | 42 | 14 (33) | 28 (67) | |
Stage | ||||
 I | 7 | 3 (43) | 4 (57) | 0.54 |
 II | 38 | 11 (29) | 27 (71) | |
 III | 17 | 4 (24) | 13 (76) | |
 IV | 38 | 10 (26) | 28 (74) | |
Histopathologic type | ||||
 Well | 64 | 15 (23) | 49 (77) | 0.25 |
 Moderately | 31 | 11 (35) | 20 (65) | |
 Poorly | 5 | 2 (40) | 3 (60) | |
Tumor site | ||||
 Gingiva | 35 | 11 (31) | 24 (69) | 0.84 |
 Tongue | 50 | 12 (24) | 38 (76) | |
 Buccal mucosa | 9 | 2 (22) | 7 (78) | |
 Oral floor | 6 | 3 (50) | 3 (50) |